Prescient Presents New Data on Key OmniCAR Features for CAR-T Cell Therapy at Cell & Gene Meeting
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell &...
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
This year, the ASX healthcare index gained a little more than 10% year to date....
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a...
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.